



THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



MEDICAMEN ORGANICS LIMITED

CORPORATE IDENTIFICATION NUMBER: U74899DL1995PLC066416

Our Company was incorporated on March 15, 1995 as "Panchdeep Pharmaceuticals Limited", a public limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated March 15, 1995 issued by the Registrar of Companies, National Capital Territory (NCT) of Delhi and Haryana. Subsequently, pursuant to a resolution passed by the Board of Directors in their meeting held on July 31, 1995 and by the Shareholders in their EGM held on October 14, 1995, the name of our Company was changed to "Medicamen Organics Limited" and a fresh certificate of incorporation dated November 14, 1995 was issued by the Registrar of Companies, Delhi and Haryana at Delhi. For details relating to change in the Registered Office of our Company, please refer to "History and Certain Corporate Matters" on page 136 of this Prospectus.

Registered Office: 10 Community Centre, No 2 Ashok Vihar, Phase II, New Delhi, Delhi, 110052, India;
Telephone: +91-9818222845; Email: cs@mediorganics.in; Website: www.medicamenorganics.com;
Contact Person: Ms. Varsha Bansal, Company Secretary & Compliance Officer;

OUR PROMOTERS: MR. BAL KISHAN GUPTA AND MR. ASHUTOSH GUPTA

BASIS OF ALLOTMENT

PUBLIC ISSUE OF 31,00,000 EQUITY SHARES OF FACE VALUE ₹ 10 EACH ("EQUITY SHARES") OF MEDICAMEN ORGANICS LIMITED ("OUR COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 34 PER EQUITY SHARE (INCLUDING A SECURITIES PREMIUM OF ₹ 24 PER EQUITY SHARE) ("ISSUE PRICE"), AGGREGATING UP TO ₹ 1054.00 LAKHS (THE "ISSUE"). 1,72,000 EQUITY SHARES AGGREGATING TO ₹ 58.48 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 29,28,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH AT AN ISSUE PRICE OF ₹ 34 PER EQUITY SHARE AGGREGATING TO ₹ 995.52 LAKHS IS HERINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.49% AND 25.02% RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10/- AND ISSUE PRICE IS ₹ 34/-
THE ISSUE PRICE IS 3.4 TIMES OF THE FACE VALUE OF THE EQUITY SHARE
ANCHOR INVESTOR ISSUE PRICE: ₹ 34 PER EQUITY SHARE THE ISSUE PRICE IS 3.4 TIMES OF THE FACE VALUE

RISKS TO INVESTORS

- We require a number of approvals, licenses, registrations and permits in the ordinary course of our business and any failure or delay in obtaining the same in a timely manner may adversely affect our operations.
- The Merchant Banker associated with the Issue has handled 25 public issues in the past two years out of which no issues closed below the Issue Price on Listing date
- Our Company's failure to maintain the quality standards of the products or keep pace with the technological developments could adversely impact our business, results of operations and financial condition.
- The Price/ Earnings ratio based on Diluted EPS for year ended March 2024 for the company at the upper end of the Price Band is 10.69.
- Weighted Average Return on Net worth for Fiscals 2024, 2023 and, 2022 is 11.72%

BID/ISSUE PERIOD

ANCHOR INVESTOR BIDDING DATE WAS: THURSDAY, JUNE 20, 2024
BID/ ISSUE OPENED ON: FRIDAY, JUNE 21, 2024
BID/ ISSUE CLOSED ON: TUESDAY, JUNE 25, 2024

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, may allocate up to 50% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RIBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 217 of Prospectus.

The bidding for Anchor Investors opened and closed on June 20, 2024. The Company received 02 Anchor Investor Application Forms from 02 Anchor Investors (including Nil mutual funds through Nil Mutual Fund schemes) for 11,84,000 Equity Shares. The Anchor Investor Allocation price was finalized at Rs. 34/- per Equity Share. A total of 8,76,000 Equity Shares were allotted under the Anchor Investor portion aggregating to Rs. 297.84 Lakhs.

The Issue (excluding Anchor Investors Portion) received 3,58,009 Applications for 2,04,25,80,000 Equity Shares (before technical rejections) resulting in 918.43 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

Detail of the Applications Received:

S. No.	Category	No. of Applications* Shares applied	No. of Equity as per Prospectus	Equity Shares Reserved Subscribed	No. of times (in Rs.)	Amount
1.	Retail-Individual Investors	337290	1349160000	10,28,000	1312.41	45,86,77,20,000
2.	Non-Institutional Investors	20656	593848000	4,40,000	1349.65	20,16,19,16,000
3.	Market Maker	1	172000	1,72,000	1.00	58,48,000
4.	Qualified Institutional Buyers (Excluding Anchor Investors)	62	99400000	5,84,000	68.08	3,379,600,000
5.	Anchor Investors	2	1184000	8,76,000	1.35	4,02,56,000
	Total	3,58,011	2,04,37,64,000	31,00,000	659.26	69,47,53,40,000

Final Demand

A summary of the final demand as per NSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

Sr. No	Bid Price	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1	32	4,736,000	0.19	4,736,000	0.19
2	33	2,828,000	0.12	7,564,000	0.31
3	34	1,628,348,000	66.98	1,635,912,000	67.30
	CUTOFF	795,024,000	32.70	2,430,936,000	100.00
	Total	2,430,936,000	100.00		

The Basis of Allotment was finalised in consultation with the Designated Stock Exchange, being National Stock Exchange of India Limited on June 26, 2024.

1) Allotment to Retail Individual Investors (After Technical Rejections)

The Basis of Allotment to the Retail Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 34/- per Equity Share, was finalised in consultation with National Stock Exchange of India Limited. The category has been subscribed to the extent of 109.54 times. The total number of Equity Shares Allotted in this category is 10,28,000 Equity Shares to 2149 successful applicants. The details of the Basis of Allotment of the said category is as under:

No. of Shares Applied for (Category Wise)	No. of application received	% of Total	Total No. of shares applied	% of Total	No. of Equity Shares Allotted per Applicant	Ratio	Total No. of Shares Allotted
Retail Individual Investor	330384	100.00	1321536000	100.00	4000	13:16712	10,28,000

2) Allotment to Non-Institutional Investors (After Technical Rejections)

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 34/- per Equity Share, was finalised in consultation with National Stock Exchange of India Limited. The category has been subscribed to the extent of 270.88 times. The total number of Equity Shares Allotted in this category is 4,40,000 Equity Shares to 718 successful applicants. The details of the Basis of Allotment of the said category is as under (Sample Basis):

No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Ratio of allottees to applicants	Total No. of shares allocated/ allotted	Surplus/ Deficit (B)-(6)
-1	-2	-3	-4	-5	-6	-7	-8	-9
8000	12576	62.45	100608000	17.21	75723	19	12576	76000
12000	2338	11.61	28056000	4.60	21116	5	2338	20000
16000	672	3.34	10752000	1.84	8093	1	336	8000
1392000	2	0.01	2784000	0.48	2095	1	2	4000
1408000	2	0.01	2816000	0.48	2119	1	2	4000
1420000	2	0.01	2840000	0.49	2138	1	2	4000
1432000	8	0.04	11456000	1.96	8622	1	4	8000
1440000	2	0.01	2880000	0.49	2168	1	2	4000
1444000	2	0.01	2888000	0.49	2174	1	2	4000
1456000	2	0.01	2912000	0.50	2192	1	2	4000
1464000	2	0.01	2928000	0.50	2204	1	2	4000
1468000	45	0.22	66060000	11.30	49720	13	45	52000

3) Allotment to QIBs excluding Anchor Investors (After Technical Rejections)

Allotment to QIBs, who have bid at the Issue Price of Rs. 34/- per Equity Share or above, has been done on a proportionate basis in consultation with National Stock Exchange of India Limited. This category has been subscribed to the extent of 108.63 times of QIB portion. The total number of Equity Shares allotted in the QIB category is 5,84,000 Equity Shares, which were allotted to 73 successful +

Applicants.

No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Ratio of allottees to applicants	Total No. of shares allocated/ allotted	Surplus/ Deficit (B)-(6)
-1	-2	-3	-4	-5	-6	-7	-8	-9
584000	3	4.84	1752000	1.76	10294	1	1	12000
588000	1	1.61	588000	0.59	3455	1	1	4000
736000	1	1.61	736000	0.74	4324	1	1	4000
888000	1	1.61	888000	0.89	5217	1	1	4000
936000	1	1.61	936000	0.94	5499	1	1	4000
1160000	1	1.61	1160000	1.17	6815	1	1	8000
1168000	15	24.19	17520000	17.63	102934	1	1	60000
						11	15	44000
1284000	1	1.61	1284000	1.29	7544	1	1	8000
1400000	1	1.61	1400000	1.41	8225	1	1	8000
1440000	1	1.61	1440000	1.45	8460	1	1	8000
1524000	1	1.61	1524000	1.53	8954	1	1	8000
1528000	1	1.61	1528000	1.54	8977	1	1	8000
1768000	2	3.23	3536000	3.56	20775	1	1	16000
						1	2	4000
1880000	1	1.61	1880000	1.89	11046	1	1	12000
1908000	2	3.23	3816000	3.84	22420	1	1	24000
2028000	3	4.84	6084000	6.12	35745	1	1	36000
2040000	1	1.61	2040000	2.05	11986	1	1	12000
2048000	3	4.84	6144000	6.18	36098	1	1	36000
2052000	22	35.48	45144000	45.42	265232	1	1	264000
TOTAL	62	100.00	99400000	100.00	584000			584000

4) Allotment to Anchor Investors (After Technical Rejections)

The Company in consultation with the BRLM has allocated 8,76,000 Equity Shares to 2 Anchor Investors at the Anchor Investor Issue Price of Rs. 34/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

Category	Fis/BANKS	MF's	IC	AIF	FIs/FPIs	NBFC'S	TOTAL
Anchor	-	-	-	4,32,000	-	4,44,000	8,76,000

5) Allotment to Market Maker (After Technical Rejections)

The Basis of Allotment to Market Maker who have bid at an Issue Price of Rs 34/- per Equity Share or above, was finalised in consultation with NSE. The category was subscribed by 1.00 times i.e. for 1,72,000 Equity Shares the total number of shares allotted in this category is 1,72,000 Equity Shares. The category wise details of the Basis of Allotment are as under:

No. of Shares Applied for (Category wise)	No. of Application Received	% of Total	Total No. of Shares Applied in each Category	% to Total	Total No. of Shares Allotted	Ratio
1,72,000	1	100	1,72,000	100	1,72,000	1
Total	1	100	1,72,000	100	1,72,000	1

The Board of Directors of our Company at its meeting held on June 26, 2024 has taken on record the basis of allotment of Equity Shares approved by the designated stock exchange, being National Stock Exchange of India Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs shall be dispatched/ mailed for unblocking of funds and transfer to the Public Issue Account on or before June 27, 2024 and payment to non-Syndicate brokers shall be issued on June 27, 2024. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before June 27, 2024 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from National Stock Exchange of India Limited and the trading of the Equity Shares is expected to commence on June 28, 2024.

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated June 26, 2024 filed with the Registrar of Companies, Delhi and Haryana ("RoC").

INVESTORS, PLEASE NOTE

The details of the allotment made has been hosted on the website of the Registrar to the Issue, KFINTECH LIMITED at website: <https://www.kfintech.com/>

All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sole Bidder Serial number of the ASBA form, number of Equity Shares bid for, Bidder DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and copy of the Acknowledgment Slip received from the Designated Intermediary and payment details at the address given below:

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 GYR CAPITAL ADVISORS PRIVATE LIMITED Address: 428, Gala Empire, Near JB Tower, Drive in Road, Thaltej, Ahmedabad - 380 054, Gujarat, India. Telephone: +91 87775 64648 Facsimile: N.A. E-mail: info@gyrcapitaladvisors.com Website: www.gyrcapitaladvisors.com Investor grievance: investors@gyrcapitaladvisors.com Contact Person: Mohit Baid SEBI Registration Number: INM000012810 CIN: U67200GJ2017PTC096908	 KFIN TECHNOLOGIES LIMITED Selenium Tower-B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad-500 032, Telangana, India. Tel No.: +91 40 6716 2222 Facsimile: N.A. Fax: +91 4023431551 Email: nvl ipo@kfintech.com Website: www.kfintech.com Investor grievance: investors@gyrcapitaladvisors.com Investor Grievance Email: einward.ris@kfintech.com Contact Person: Mr. M Murali Krishna SEBI Registration No.: INR000002221	 Ms. Varsha Bansal , is the Company Secretary and Compliance Officer of our Company. His contact details are set forth hereunder: 10 Community Centre No 2 Ashok Vihar Phase II, New Delhi, Delhi, 110052, India. Telephone: +91-9818222845, Facsimile: N.A. E-mail: cs@mediorganics.in Investors can contact the Company Secretary and Compliance Officer of the BRLM or the Registrar to the Issue in case of any pre-issue or post-issue related problems, such as non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account and refund orders, etc.

Place: Delhi
Date: June 26, 2024

Disclaimers: MEDICAMEN ORGANICS LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Delhi on June 26, 2024 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of NSE Emerge at https://www1.nseindia.com/emerget/index_sme.htm and is available on the websites of the BRLM at www.gyrcapitaladvisors.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page 27 of the Prospectus.
The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being offered and sold outside the United States in "offshore transactions" in reliance on Regulation under the Securities Act and the applicable laws of each jurisdiction where such offers and sales are made. There will be no public offering in the United States.

On behalf of Board of Directors
For MEDICAMEN ORGANICS LIMITED
Sd/-
Ms. Varsha Bansal
Company Secretary & Compliance Officer